Paper · 2022 · Open access

Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders.

Wanyuan Cui, Kelly‐Anne Phillips, Richard A. Anderson, Prudence A. Francis, Sherene Loi, Sibylle Loibl, Ann H. Partridge, Louise Anne Keogh

PubMed Central, 12(12), 5599–5612 · Published 1 January 2022

Open full textCite this paper

In brief

“Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders.” is a 2022 paper by Wanyuan Cui and 7 co-authors, published in PubMed Central. OpenAlex counts 2 citations as of 22 November 2026. It is open access: the full text is free to read at PubMed Central.

Citations
2
Most cited in
2023 (1)
Field-weighted impact
0.26
References
36
Authors
8

Abstract

Clinical trial endpoints are fundamental for evaluating the safety and efficacy of cancer therapies, yet it is not well understood how they are selected or the role of stakeholder groups in deciding endpoints. This study aimed to explore how clinical trial endpoints are selected in breast cancer trials of anti-cancer drugs through semi structured interviews with purposively selected stakeholders involved in breast cancer clinical trials (clinicians, consumers, pharmaceutical company representatives, and members of drug regulatory agencies). Participants were asked to describe the process of selecting trial endpoints. Interviews were transcribed verbatim and analysed using inductive thematic analysis supported by NVivo software. Saturation of the main themes was reached and the final sample included 25 participants from 14 countries (9 clinicians, 7 consumers, 5 members of regulatory agencies, 4 pharmaceutical company representatives). Pharmaceutical companies were almost always identified as the main decision maker. While most consumers and pharmaceutical company representatives felt clinicians and consumers influenced trial design, some clinicians and regulators reported consumers and clinicians had little influence. Factors identified as important considerations in determining trial endpoints included the main goal of the trial, established standardised endpoints, resources, and the investigational agent studied. All pharmaceutical advisors reported that meeting the requirements for regulatory approval was the major factor considered. Clinical trial endpoint selection is largely decided by the pharmaceutical industry, driven by requirements for regulatory approval. Given the limited influence from clinicians and consumers, guidance by regulatory agencies will be important for future inclusion of novel endpoints in clinical trials.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cui, W., Phillips, K., Anderson, R. A., Francis, P. A., Loi, S., Loibl, S., Partridge, A. H., & Keogh, L. A. (2022). Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders. PubMed Central, 12(12), 5599–5612. https://pmc.ncbi.nlm.nih.gov/articles/PMC9827081/

MLA 9

Cui, Wanyuan, et al. “Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders.” PubMed Central, vol. 12, no. 12, 2022, pp. 5599–5612. https://pmc.ncbi.nlm.nih.gov/articles/PMC9827081/.

Chicago

Cui, Wanyuan, Kelly‐Anne Phillips, Richard A. Anderson, Prudence A. Francis, Sherene Loi, Sibylle Loibl, Ann H. Partridge, and Louise Anne Keogh. 2022. “Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders.” PubMed Central 12 (12): 5599–5612. https://pmc.ncbi.nlm.nih.gov/articles/PMC9827081/.

Harvard

Cui, W. et al. (2022) ‘Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders.’, PubMed Central, 12(12), pp. 5599–5612. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9827081/.

IEEE

W. Cui et al., “Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders.,” PubMed Central, vol. 12, no. 12, pp. 5599–5612, 2022.

BibTeX

@article{cui2022selection,
  title     = {{Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders.}},
  author    = {Cui, Wanyuan and Phillips, Kelly‐Anne and Anderson, Richard A. and Francis, Prudence A. and Loi, Sherene and Loibl, Sibylle and Partridge, Ann H. and Keogh, Louise Anne},
  journal   = {PubMed Central},
  year      = {2022},
  volume    = {12},
  number    = {12},
  pages     = {5599--5612},
  url       = {https://pmc.ncbi.nlm.nih.gov/articles/PMC9827081/}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials

  • breast cancer clinical trials
  • anticancer agents
  • stakeholder perspectives
  • pharmaceutical industry influence
  • drug regulatory agencies
  • clinician engagement
  • consumer involvement
  • trial design

Work with this paper

Most-cited papers in Mathematics

All highly cited Mathematics papers

Questions about this paper

How do I cite this paper in APA style?

Cui, W., Phillips, K., Anderson, R. A., Francis, P. A., Loi, S., Loibl, S., Partridge, A. H., & Keogh, L. A. (2022). Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders. PubMed Central, 12(12), 5599–5612. https://pmc.ncbi.nlm.nih.gov/articles/PMC9827081/

How many times has this paper been cited?

2 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the full text from this page.

Who wrote this paper?

Wanyuan Cui, Kelly‐Anne Phillips, Richard A. Anderson, Prudence A. Francis, Sherene Loi, Sibylle Loibl, Ann H. Partridge, Louise Anne Keogh.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.